These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
300 related articles for article (PubMed ID: 26690113)
41. Synthesis and preclinical evaluation of an 18F labeled PDE7 inhibitor for PET neuroimaging. Thomae D; Servaes S; Vazquez N; Wyffels L; Dedeurwaerdere S; Van der Veken P; Joossens J; Augustyns K; Stroobants S; Staelens S Nucl Med Biol; 2015 Dec; 42(12):975-81. PubMed ID: 26330158 [TBL] [Abstract][Full Text] [Related]
42. Synthesis and radiopharmacological evaluation of a high-affinity and metabolically stabilized 18F-labeled bombesin analogue for molecular imaging of gastrin-releasing peptide receptor-expressing prostate cancer. Richter S; Wuest M; Krieger SS; Rogers BE; Friebe M; Bergmann R; Wuest F Nucl Med Biol; 2013 Nov; 40(8):1025-34. PubMed ID: 23969085 [TBL] [Abstract][Full Text] [Related]
43. Quantitative studies using positron emission tomography (PET) for the diagnosis and therapy planning of oncological patients. Dimitrakopoulou-Strauss A; Strauss L Hell J Nucl Med; 2006; 9(1):10-21. PubMed ID: 16617388 [TBL] [Abstract][Full Text] [Related]
45. The role of positron emission tomography using carbon-11 and fluorine-18 choline in tumors other than prostate cancer: a systematic review. Treglia G; Giovannini E; Di Franco D; Calcagni ML; Rufini V; Picchio M; Giordano A Ann Nucl Med; 2012 Jul; 26(6):451-61. PubMed ID: 22566040 [TBL] [Abstract][Full Text] [Related]
46. Development of Amino Acid-Based Radiopharmaceuticals for Tumor Imaging. Zhu J; Song X; Zhang J Mini Rev Med Chem; 2018; 18(7):561-583. PubMed ID: 27121713 [TBL] [Abstract][Full Text] [Related]
47. PET tracers and radiochemistry. Schlyer DJ Ann Acad Med Singap; 2004 Mar; 33(2):146-54. PubMed ID: 15098627 [TBL] [Abstract][Full Text] [Related]
48. Monitoring reversal of MET-mediated resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer using 3'-deoxy-3'-[18F]-fluorothymidine positron emission tomography. Iommelli F; De Rosa V; Gargiulo S; Panico M; Monti M; Greco A; Gramanzini M; Ortosecco G; Fonti R; Brunetti A; Del Vecchio S Clin Cancer Res; 2014 Sep; 20(18):4806-15. PubMed ID: 25052479 [TBL] [Abstract][Full Text] [Related]
49. In Vivo Assessment of Ovarian Tumor Response to Tyrosine Kinase Inhibitor Pazopanib by Using Hyperpolarized Ravoori MK; Singh SP; Lee J; Bankson JA; Kundra V Radiology; 2017 Dec; 285(3):830-838. PubMed ID: 28707963 [TBL] [Abstract][Full Text] [Related]
50. Synthesis, characterization, and monkey positron emission tomography (PET) studies of [18F]Y1-973, a PET tracer for the neuropeptide Y Y1 receptor. Hostetler ED; Sanabria-Bohórquez S; Fan H; Zeng Z; Gantert L; Williams M; Miller P; O'Malley S; Kameda M; Ando M; Sato N; Ozaki S; Tokita S; Ohta H; Williams D; Sur C; Cook JJ; Burns HD; Hargreaves R Neuroimage; 2011 Feb; 54(4):2635-42. PubMed ID: 21078401 [TBL] [Abstract][Full Text] [Related]
51. Recent progress in the imaging of c-Met aberrant cancers with positron emission tomography. Floresta G; Abbate V Med Res Rev; 2022 Jul; 42(4):1588-1606. PubMed ID: 35292998 [TBL] [Abstract][Full Text] [Related]
53. Synthesis of [18F]Xeloda as a novel potential PET radiotracer for imaging enzymes in cancers. Fei X; Wang JQ; Miller KD; Sledge GW; Hutchins GD; Zheng QH Nucl Med Biol; 2004 Nov; 31(8):1033-41. PubMed ID: 15607485 [TBL] [Abstract][Full Text] [Related]
54. Theragnostic imaging using radiolabeled antibodies and tyrosine kinase inhibitors. Yoshimoto M; Kurihara H; Fujii H ScientificWorldJournal; 2015; 2015():842101. PubMed ID: 25874259 [TBL] [Abstract][Full Text] [Related]
55. RGD-based PET tracers for imaging receptor integrin αv β3 expression. Cai H; Conti PS J Labelled Comp Radiopharm; 2013 May; 56(5):264-79. PubMed ID: 24285371 [TBL] [Abstract][Full Text] [Related]
56. Tyrosine-Kinase Inhibitors Therapies with Mainly Anti-Angiogenic Activity in Advanced Renal Cell Carcinoma: Value of PET/CT in Response Evaluation. Ranieri G; Marech I; Niccoli Asabella A; Di Palo A; Porcelli M; Lavelli V; Rubini G; Ferrari C; Gadaleta CD Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28891933 [TBL] [Abstract][Full Text] [Related]
57. Molecular PET and PET/CT imaging of tumour cell proliferation using F-18 fluoro-L-thymidine: a comprehensive evaluation. Barwick T; Bencherif B; Mountz JM; Avril N Nucl Med Commun; 2009 Dec; 30(12):908-17. PubMed ID: 19794320 [TBL] [Abstract][Full Text] [Related]
58. Radiosynthesis and radiopharmacological evaluation of cyclin-dependent kinase 4 (Cdk4) inhibitors. Koehler L; Graf F; Bergmann R; Steinbach J; Pietzsch J; Wuest F Eur J Med Chem; 2010 Feb; 45(2):727-37. PubMed ID: 19954867 [TBL] [Abstract][Full Text] [Related]
59. Radiolabeled COX-2 inhibitors for non-invasive visualization of COX-2 expression and activity--a critical update. Laube M; Kniess T; Pietzsch J Molecules; 2013 May; 18(6):6311-55. PubMed ID: 23760031 [TBL] [Abstract][Full Text] [Related]
60. Synthesis of [18F]SU11248, a new potential PET tracer for imaging cancer tyrosine kinase. Wang JQ; Miller KD; Sledge GW; Zheng QH Bioorg Med Chem Lett; 2005 Oct; 15(19):4380-4. PubMed ID: 16019210 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]